US patients treated with elranatamab in the RW setting were heavily pre-treated. RW treatment patterns suggest less frequent administration of elranatamab compared with the label and effectiveness consistent with clinical trial results (MagnetisMM-3 trial NCT04649359).
Banerjee et al. (Thu,) studied this question.